Roxwood Medical, Inc

Roxwood Medical, Inc designs and manufactures advanced medical devices aimed at improving patient outcomes in healthcare settings, combining innovation with strategic solutions for clinicians. Founded in 2007 and headquartered in Redwood City, US, Roxwood Medical focuses on developing specialized medical devices. The company has not reported any significant changes in its business strategy and does not have known subsidiaries. Douglas Hansmann is noted as the founder.

Roxwood completed 3 deals with its latest funding round being a Series C in July 2016, raising USD 2. 49 mn, bringing the total amount raised to USD 2. 49 mn, with a current valuation of USD 30. 89 mn.

Roxwood Medical specializes in innovative medical devices that address specific challenges in the healthcare industry. Their core offerings include advanced solutions designed to enhance operational efficiency and improve patient care. These products cater to a diverse clientele, focusing on critical areas such as patient monitoring and surgical procedures, primarily serving clients in North America and Europe within the healthcare sector. The company's offerings have evolved through regular updates and feature releases, ensuring they meet the demands of a dynamic market.

The company generates revenue through a structured business model that includes both direct sales and agreements for its medical devices. Clients typically engage in multi-year contracts, ensuring sustained access to Roxwood's flagship products. This approach not only establishes a recurring revenue stream but also fosters long-term relationships with healthcare providers, allowing for tiered pricing based on client needs and product features, thus maintaining a steady flow of income. Looking ahead, Roxwood Medical plans to launch new advanced medical devices that are currently in development, although no specific release dates have been disclosed.

The company aims to expand into new geographic markets, particularly focusing on opportunities in Asia by 2025. The recent Series C funding of USD 2. 49 mn will support these initiatives, enabling the company to enhance its product offerings and facilitate market entry strategies.